Keywords: Orexo, ProStrakan, Kyowa Hakko Kirin, Abstral, Brakthough pain, Cancer patients, Commercial rights

Orexo and ProStrakan reconfigure rights to Abstral

Article | 04 June 2012

Print This

Sweden’s Orexo AB (STO: ORX) and Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) have ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in